1. CD19 cell count at baseline predicts B cell repopulation at 6 and 12 months in multiple sclerosis patients treated with Ocrelizumab;Abbadessa;Int. J. Environ. Res. Public Health.,2021
2. Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis;Capasso;Mult. Scler. Relat. Disord.,2021
3. Cellerino, M., et al., 2021. Predictors of ocrelizumab effectiveness in patients with Multiple Sclerosis. Neurotherapeutics. 1–10. Advance online publication. 10.1007/s13311-021-01104-8.
4. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
5. Effect of Ocrelizumab in blood leukocytes of patients with primary progressive MS;Fernández-Velasco;Neurol. Neuroimmunol. Neuroinflamm.,2021